Skip to main content

Medications for Non-Small Cell Lung Cancer - Page 3

The medications listed below are related to or used in the treatment of this condition.

Filter
Drug name Rating Reviews Activity ? Rx/OTC Pregnancy CSA Alcohol
Mekinist Rate Add review
Rx D N
Generic name:
trametinib systemic
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
Mektovi Rate Add review
Rx N
Generic name:
binimetinib systemic
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
methotrexate Rate Add review
Rx X N X
Generic name:
methotrexate systemic
Brand name:
Trexall
Drug class:
antimetabolites, antirheumatics, antipsoriatics, other immunosuppressants
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
mobocertinib Rate Add review
Rx N
Generic name:
mobocertinib systemic
Drug class:
EGFR inhibitors
For consumers:
dosage, interactions, side effects
Mvasi Rate Add review
Rx C N
Generic name:
bevacizumab systemic
Drug class:
VEGF/VEGFR inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
Navelbine Rate Add review
Rx D N
Generic name:
vinorelbine systemic
Drug class:
mitotic inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
necitumumab 10 1 review for necitumumab to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
necitumumab systemic
Brand name:
Portrazza
Drug class:
EGFR inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
nivolumab 5.2 47 reviews for nivolumab to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
nivolumab systemic
Brand name:
Opdivo
Drug class:
anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Opdivo 4.9 32 reviews for Opdivo to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
nivolumab systemic
Drug class:
anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
osimertinib 7.3 37 reviews for osimertinib to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
osimertinib systemic
Brand name:
Tagrisso
Drug class:
EGFR inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
paclitaxel protein-bound 1.0 1 review for paclitaxel protein-bound to treat Non-Small Cell Lung Cancer
Rx D N
Generic name:
paclitaxel protein-bound systemic
Brand name:
Abraxane
Drug class:
mitotic inhibitors
For consumers:
dosage, interactions, side effects
paclitaxel 7.0 1 review for paclitaxel to treat Non-Small Cell Lung Cancer
Rx D N
Generic name:
paclitaxel systemic
Drug class:
mitotic inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
pembrolizumab 4.4 100 reviews for pembrolizumab to treat Non-Small Cell Lung Cancer
Rx D N
Generic name:
pembrolizumab systemic
Brand name:
Keytruda
Drug class:
anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
pemetrexed 9.0 2 reviews for pemetrexed to treat Non-Small Cell Lung Cancer
Rx D N
Generic name:
pemetrexed systemic
Brand names:
Alimta, Pemfexy, Pemrydi RTU
Drug class:
antimetabolites
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
Pemfexy Rate Add review
Rx D N
Generic name:
pemetrexed systemic
Drug class:
antimetabolites
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
Pemrydi RTU Rate Add review
Rx D N
Generic name:
pemetrexed systemic
Drug class:
antimetabolites
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
Photofrin Rate Add review
Rx C N
Generic name:
porfimer systemic
Drug class:
malignancy photosensitizers
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
porfimer Rate Add review
Rx C N
Generic name:
porfimer systemic
Brand name:
Photofrin
Drug class:
malignancy photosensitizers
For consumers:
dosage, interactions, side effects
Portrazza Rate Add review
Rx N
Generic name:
necitumumab systemic
Drug class:
EGFR inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
pralsetinib Rate Add review
Rx N
Generic name:
pralsetinib systemic
Brand name:
Gavreto
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
ramucirumab Rate Add review
Rx C N
Generic name:
ramucirumab systemic
Brand name:
Cyramza
Drug class:
VEGF/VEGFR inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
repotrectinib Rate Add review
Rx N
Generic name:
repotrectinib systemic
Brand name:
Augtyro
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Retevmo 10 4 reviews for Retevmo to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
selpercatinib systemic
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
Rozlytrek Rate Add review
Rx N
Generic name:
entrectinib systemic
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
Rybrevant 9.0 2 reviews for Rybrevant to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
amivantamab systemic
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information

Frequently asked questions

View more FAQ

Learn more about Non-Small Cell Lung Cancer

Care guides

Symptoms and treatments

Legend

Rating For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).
Activity Activity is based on recent site visitor activity relative to other medications in the list.
Rx Prescription only.
OTC Over-the-counter.
Rx/OTC Prescription or Over-the-counter.
Off-label This medication may not be approved by the FDA for the treatment of this condition.
EUA An Emergency Use Authorization (EUA) allows the FDA to authorize unapproved medical products or unapproved uses of approved medical products to be used in a declared public health emergency when there are no adequate, approved, and available alternatives.
Expanded Access Expanded Access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
Pregnancy Category
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
B Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
C Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
D There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
X Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits.
N FDA has not classified the drug.
Controlled Substances Act (CSA) Schedule
M The drug has multiple schedules. The schedule may depend on the exact dosage form or strength of the medication.
U CSA Schedule is unknown.
N Is not subject to the Controlled Substances Act.
1 Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision.
2 Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence.
3 Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence.
4 Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3.
5 Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4.
Alcohol
X Interacts with Alcohol.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.